Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers; and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Metrics to compare | APRE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAPREPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −0.5x | −0.5x | |
PEG Ratio | −0.02 | −0.06 | 0.00 | |
Price/Book | 0.6x | 1.7x | 2.6x | |
Price / LTM Sales | 7.3x | 8.7x | 3.3x | |
Upside (Analyst Target) | - | 303.3% | 43.4% | |
Fair Value Upside | Unlock | 8.5% | 7.1% | Unlock |